Mark Schoenberg Sells 60,677 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. The trade was a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Stock Up 0.4%

NASDAQ:URGN opened at $46.36 on Wednesday. The firm has a market capitalization of $2.27 billion, a PE ratio of -23.41 and a beta of 1.57. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81. The firm has a 50-day moving average price of $41.11 and a 200 day moving average price of $29.51.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to the consensus estimate of $63.55 million. On average, research analysts expect that Urogen Pharma will post -0.2 EPS for the current year.

Institutional Investors Weigh In On Urogen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. California State Teachers Retirement System raised its position in Urogen Pharma by 4,168.7% in the 2nd quarter. California State Teachers Retirement System now owns 1,654,123 shares of the company’s stock valued at $60,872,000 after purchasing an additional 1,615,373 shares during the last quarter. Wellington Management Group LLP boosted its stake in Urogen Pharma by 15.1% in the second quarter. Wellington Management Group LLP now owns 115,362 shares of the company’s stock worth $4,245,000 after purchasing an additional 15,147 shares in the last quarter. Palo Alto Investors LP acquired a new position in Urogen Pharma in the second quarter worth $901,600,000. Coastal Bridge Advisors LLC bought a new stake in shares of Urogen Pharma during the second quarter worth $1,362,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Urogen Pharma during the second quarter worth $80,947,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on URGN. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. UBS Group restated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Oppenheimer increased their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 target price for the company. Finally, TD Cowen lifted their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.38.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.